What Does Big Pharma Think About Patient Centricity?
At the 2018 Financial Times Pharmaceutical and Biotechnology Conference, there was a lot of buzz around ‘patient centricity’ and all of the big pharma companies were determined to broadcast their…
Brian Hilberdink, President of Novo Nordisk Canada, calls for collaboration between government and industry to ensure that Canadian patients get swift access to the best treatments. As a Canadian who spent several years working globally for a biopharmaceutical company, I…
At the 2018 Financial Times Pharmaceutical and Biotechnology Conference, there was a lot of buzz around ‘patient centricity’ and all of the big pharma companies were determined to broadcast their…
There are around 2 billion people in the world that do not have access to the medicines they need. This week the 2018 Access to Medicine Index was published revealing…
Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the United States, discusses the contradictory nature of Trump’s efforts to lower drug prices. …
Antonio Bernal, president of the General Patient Alliance (AGP), discusses the role of the patient voice in the Spanish healthcare system and how the alliance is the bridge between the patient associations and the administration. Furthermore, he highlights the evolution of the Alliance and how the strength of the patients is gaining momentum. Can you start by giving us…
K P Tsang, president of the Hong Kong Alliance for Rare Diseases (HKARD), shares the challenges faced by patients with rare diseases and their caregivers in Hong Kong, the areas…
Stanimir Hasurdjiev explains the key role of the National Patients’ Organization (NPO) in Bulgaria and discusses the main areas that he is working on to ensure that patients are heard…
France’s patient advocacy network is one of Europe’s most well-developed and formalised. Patient advocacy groups – including the three featured below – fill in research, care, and support gaps left…
The global pharma industry is facing increased pressure to ensure lifesaving medications reach underserved populations. Drawing from a new Access to Medicine Foundation report, AMF Head of Research Claudia Martinez…
Writing in the June 2025 edition of DIA’s Global Forum Magazine, Finn McCartney, Maria Dutarte, Petra Adámková, and Paola Kruger from the European Patients’ Academy on Therapeutic Innovation (EUPATI) weigh…
The Promising Pathways Act 2.0 is a newly proposed bill that aims to expedite and streamline approval pathways for rare disease therapies in the US. The Act is, however, facing…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Patients and carers with lived experience of a disease have valuable insights to share with physicians and drug developers alike. This is especially true of rare diseases, defined in the…
See our Cookie Privacy Policy Here
